Despite ENMD- 2076 did not meet the efficacy bar set in this trial, this AURKA inhibitor has been reported as potentially advantageous for ovarian clear cell carcinomas patients with ARID1A deficiency (28). This evidence concerns the gene ARID1A and ovarian clear cell cancer.